Abstract. Provision of suf®cient available iron is a prerequisite to ensure the optimal response to recombinant human erythropoietin (rHuEpo). Functional iron de®ciency (a state when iron supply is reduced to meet the demands for increased erythropoiesis) is the common cause of rHuEpo hyporesponsiveness in dialysis patients who have normal iron status, even when they are iron-overloaded. Iron supplementation is not justi®ed for this hyporesponsiveness in patients with iron overload due to the potential hazards of iron overload aggravated by intravenous iron therapy. Furthermore, in vivo studies indicated that the promising effect of intravenous iron medication to overcome iron-de®cient erythropoiesis is not observed in iron-overloaded haemodialysis (HD) patients. Ascorbic acid, a water-soluble antioxidant as well as a reducing agent, has a number of associations with iron metabolism. Recent research highlights that ascorbic acid can potentiate the mobilization of iron from inert tissue stores and facilitates the incorporation of iron into protoporphyrin in iron-overloaded HD patients being treated with rHuEpo. Interest has turned towards the use of ascorbic acid as an adjuvant therapy in this ®eld. This review focuses on the improvement of rHuEpo response by administration of ascorbic acid and discusses its clinical implications and potential issues for nephrologists.
Introduction
The potential role of adjuvant therapies in enhancing the effectiveness of recombinant human erythropoietin (rHuEpo) in patients with end-stage renal disease (ESRD) has received increasing attention in recent years. The important reason for adjuvant therapies is that they may help to overcome rHuEpo hyporesponsiveness, allowing patients to achieve increased haemoglobin concentration and derive more costeffectiveness and greater clinical bene®ts from rHuEpo treatment. Recent research highlights the usefulness of adjuvant therapies, including vitamins, hormones and cytokines w1x. Some vitamins may generate an ongoing supply of healthy red blood cells w2±5x. This review emphasizes a role for vitamin C as an adjuvant therapy in dialysis patients being treated with rHuEpo and discusses its possible mechanisms and clinical implications, and the potential issues of ascorbic acid medication.
rHuEpo hyporesponsiveness in dialysis patients with iron overload
Insuf®cient iron storageuavailability is the most common cause of suboptimal response to rHuEpo. Guidelines for the management of rHuEpo hyporesponsiveness suggest a serum ferritin level of 100 mgul as the diagnostic threshold for iron de®ciency in haemodialysis (HD) patients w6,7x. Studies from Fishbane et al. w8x and Tarng et al. w9x indicated that the quantity of available iron for prompt erythropoiesis is inadequate in most HD patients when current guidelines for serum ferritin and transferrin saturation (TS) are used. Furthermore, cumulative data recommend that it is crucial to maintain serum ferritin )300 mgul for the optimal response since there is great need for iron in Epo-stimulated erythroid progenitor cells w10±13x. However, HD patients with increased iron stores may exhibit rHuEpo hyporesponsiveness due to impaired iron availability. The ferritin level to indicate iron overload in dialysis patients is suggested to be 500±1000 mgul w14±16x. Iron overload not only increases cardiovascular and infectious morbidity w17,18x, but may sometimes cause relative resistance to rHuEpo in HD patients. The mechanism of this hyporesponsiveness remains unclear, but inadequate iron mobilization and defective iron utilization are the possible reasons. El-Reshaid et al. found that the rHuEpo dose required to maintain the target haemoglobin level is nearly twice as large in patients with severe iron overload (ferritin )1100 mgul) as in controls (ferritin 100±600 mgul) w19x. They further observed that TS decreased to a level of -30% in six (55%) of 11 iron-overloaded patients. Ali et al. also showed that marrow iron stores were depleted in 10 HD patients with a mean ferritin of 1336 mgul w20x.
Investigators reported that iron-de®cient erythropoiesis can be overcome by iv iron therapy in patients with ferritin )500 mgul w15,21x. However, this bene®cial effect is not observed by Tarng et al. w22x, Rosenlo Èf et al. w23x or Goch et al. w24x. Similar results were also found in scorbutic animals w25x. Supplementation of iron did not improve the anaemia, but increased deposition of haemosiderin in the spleen and small intestine. After long-term iv administration of iron dextran in 36 HD patients, Ali et al. found a paradox of hepatosplenic iron overload and marrow iron depletion w20x. They proposed that the bulk of iv iron dextran is taken up by the liver and spleen, and that the hepatosplenic iron stores fail to be mobilized to the bone marrow. Iron supplementation is not warranted in patients with iron overload since tissue deposition of iron is suf®cient enough to cause organ damage. In view of the risks related to iron overload exaggerated by iv iron supplementation, an adjuvant therapy is needed to improve the rHuEpo response without hazardous side effects.
Intravenous ascorbic acid improves rHuEpo responsiveness
Bothwell et al. reported that Bantu subjects with scurvy had excessive iron deposits in tissues, which modi®ed the metabolism of ascorbic acid w26x. Tissue concentration of vitamin C is often decreased in patients with iron overload, perhaps due to increased vitamin oxidation catalysed by iron. Moreover, subclinical vitamin C de®ciency is frequently encountered in HD patients owing to insuf®cient dietary intake, loss through the dialyser and uraemia-associated metabolic derangement w27x. Thus, systemic supplementation of ascorbic acid is essential. It has recently been reported that resistant anaemia was corrected by iv administration of ascorbic acid in HD patients who had functional iron de®ciency, even when they were overloaded with iron w2,3x. We treated 12 rHEporesistant, iron-overloaded patients with ascorbic acid (300 mg iv post-dialysis, three times a week) w13x. After 8 weeks of treatment, the haematocrit had increased signi®cantly, with a concomitant signi®cant rise in TS, and a decrease in erythrocyte zinc protoporphyrin (E-ZnPP). We also compared the effects of iv iron administration with those of iv ascorbic acid in 27 rHEpo-resistant HD patients with serum ferritin )500 mgul w22x. Patients were allocated to one of two protocols: iv iron sucrose 100 mg 3 5 doses (ns15), or iv ascorbic acid 300 mg three times weekly for 8 weeks (ns12). Short-term iv iron supplementation in these patients neither improved erythropoiesis nor reduced rHuEpo dose. In contrast, iv ascorbic acid led to a signi®cant increase in haematocrit and a reduction in the requirement for rHuEpo.
Effect of iv ascorbic acid on iron metabolism
Ascorbic acid, a reducing agent, is able to release iron from ferritin and mobilize iron from the reticuloendothelial system to transferrin w2,3,13x. This leads to an increased iron availability. Protoporphyrin is an intermediate in haem biosynthesis and the mechanism of iron incorporation for haem synthesis is enzymatic. Goldberg indicated that ascorbic acid plays a role in maintaining haemoglobin iron in the reduced state and potentiates the enzymatic iron incorporation into protoporphyrin w28x. Possible explanations for the effect of ascorbic acid on the improvement of rHuEpo response include increased mobilization of iron from inert tissue stores, and increased iron utilization in the erythron (Figure 1 ).
To determine whether there is any index that can predict which patients will require iv ascorbic acid therapy, we further studied 65 iron-overloaded patients w29x. The treatment group (ns46) comprised of patients hyporesponsive to rHuEpo who received ascorbic acid 300 mg three times weekly for 8 weeks. Controls (ns19) had a haematocrit of )30% and did not receive the adjuvant therapy. Thirteen patients (four controls and nine ascorbic acid-treated patients) had withdrawn by the end of the study. The results showed that 18 of the remaining 37 ascorbic acid-treated patients had a good response, with a dramatic rise in haematocrit (26.4"1.8% vs 31.6"2.8%; P-0.001) after 8 weeks and a concomitant 24% reduction in rHuEpo dose. The enhanced erythropoiesis paralleled a rise in TS, from 27"10 to 48"19%, and a fall in E-ZnPP, from 123"44 to 70"13 mmolumol haem (P-0.05). In poor responders and in controls, there were no signi®cant changes in mean haematocrit, TS or E-ZnPP values. The receiver operating curves used to analyse the 37 patients (18 responders and 19 non-responders) showed that two indices predicted the response to iv ascorbic acid supplementation: E-ZnPP)105 mmolumol haem and TS-25%. We concluded that when rHuEpo hyporesponsiveness occurs in HD patients with iron overload, the above values should be used to guide treatment with iv ascorbic acid.
Other potential bene®ts of iv ascorbic acid
Nowadays, hyperferritinaemia in dialysis patients is always attributed to previous multiple transfusions and over-treatment with iv iron if a state of in¯amma-tion, liver disease or malignancy is excluded. Cellular iron overload plays an important role in a number of pathological states. It produces a variety of deleterious effects, including haemosiderosis, hepatic and cardiac dysfunction, and cardiovascular and infectious complication w17,18,30x. Anaemia improved and serum ferritin levels declined simultaneously after 8 weeks of iv ascorbic acid medication w29x. This implies that iv ascorbic acid may also reduce the magnitude of iron overload in uraemic patients. Confronted with the potential hazards of iron overload, iv ascorbic acid, mimicking an iron-chelating agent, provides an additional bene®t for HD patients. Ascorbic acid combined with desferrioxamine (DFO) results in very ef®cient removal of iron in non-uraemic patients with iron overload w31,32x. Studies indicated that DFO can enhance burst-forming unit-erythroid proliferation w33x and improve anaemia in iron-overloaded HD patients w34x. Therefore, long-term iv ascorbic acid alone or combined with DFO appears to be promising in the treatment of HD patients with iron overload.
It has been shown that endothelial vasomotor function is abnormal in the setting of atherosclerosis. Increased oxidative stress is implicated as one potential mechanism for this observation. Vitamin C, the main water-soluble anti-oxidant in human plasma, effectively scavenges reactive oxygen species and plays a pivotal role in the regulation of intracellular redox state. Cumulative data showed that vitamin C can improve endothelial vasomotor dysfunction in patients with risk factors for coronary heart disease and in those with coronary artery disease w35,36x. Accelerated atherosclerosis is a well-known complication in HD patients. Also, there is evidence of increased oxidative stress and enhanced susceptibility of low-density lipoprotein to oxidation in these patients. These factors have been associated with endothelial dysfunction, which is regarded as an important early event in atherogenesis w35±37x. Accordingly, improved vascular endothelial function with supplementation of ascorbic acid could potentially reduce the risk of atherosclerotic disease and coronary events in ESRD patients.
Potential problems of ascorbic acid treatment in ESRD patients
Certain laboratory and clinical observations proposed concern about the safety of using ascorbic acid in patients with severe iron overload. Cardiac death w38x and deterioration of cardiac function w39x have been reported in thalassaemic children receiving DFO and ascorbic acid. However, similar ®ndings were not observed in non-thalassaemic adults with transfusional iron overload during chelation therapy w40x. Despite the fact that untoward cardiac events associated with ascorbic acid may not be a potential problem in uraemic patients, we recommend the evaluation and follow-up of cardiac function, particularly when ascorbic acid is being administered intravenously on a weekly basis.
There are concerns that ascorbic acid promotes electron exchange and it can be shown in vitro to enhance the iron toxicity to cellular constituents. However, Proteggente et al. showed no compelling evidence for a pro-oxidant effect of ascorbic acid supplementation, in either the presence or absence of iron, on DNA base damage in healthy subjects w41x. Berger et al. further indicated that ascorbic acid exhibits antioxidant activity in iron-overloaded human plasma w42x. In our preliminary study (unpublished data), we also observed that leukocyte DNA damage was not exaggerated by iv ascorbic acid medication in HD patients with serum ferritin of )500 mgul.
Vitamin C overdose may cause secondary oxalosis w43x, leading to plasma levels of oxalate at which deposition of calcium oxalate in tissue can occur. The use of excessive amounts of vitamin C should be avoided in ESRD patients. The available data suggest that a daily dose of ascorbic acid not exceeding 150 mg is considered safe in uraemics w44x. The dose of ascorbic acid in our studies was 300 mg three times weekly, which is less than the recommended dosage. Furthermore, plasma oxalate concentration did not signi®c-antly change, although a trend towards a difference between baseline and 8 weeks was noted w29x.
Conclusions
Haemodialysis may be associated with subclinical vitamin C de®ciency, and some investigators recommend routine vitamin C supplementation for HD patients, whether or not they are receiving rHuEpo. A daily dose of 100±200 mg is recommended in some reports w44x, but prescription of ascorbic acid in different dialysis facilities varies between 55 and 1000 mg daily w45± 47x. Based on the consensus of the workshop chaired by Professor Ho È rl in the Second European Epoetin Symposium w1x, the recommendations are summarized as follows:
. When subclinical vitamin C de®ciency is suspected, ESRD patients not on dialysis should receive oral ascorbic acid 1±1.5 guweek, and HD patients should receive the same regimen, or iv ascorbic acid 300 mg three times weekly at the end of dialysis. . In iron-overloaded HD patients with rHuEpo hyporesponsiveness, E-ZnPP of )105 mmolumol haem and TS of -25% should be used to guide the iv ascorbic acid treatment. . In the long term, high doses of ascorbic acid could lead to oxalate accumulation. However, preliminary data suggest that this potential hazard can be prevented by avoiding vitamin B 6 de®ciency w48x.
